Advertisement

The Italian severe/uncontrolled asthma registry (RItA): A 12-month clinical follow-up

Published:October 28, 2022DOI:https://doi.org/10.1016/j.rmed.2022.107030

      Highlights

      • Registries collect information for preventive, diagnostic, therapeutic strategies.
      • Patient-level longitudinal data allowed to identify predictors of clinical patterns.
      • Regular review allows for thorough patients' clinical characterization and management.

      Abstract

      Background

      follow-up studies on registries of severe/uncontrolled asthma (SUA) patients are scanty.

      Objective

      to analyze baseline and follow-up characteristics of SUA patients and their longitudinal patterns.

      Methods

      180 adult patients (age ≥15 yrs) were investigated at baseline and 12-month follow-up through the Italian SUA registry (RItA).
      Latent transition analysis (LTA) was performed to detect cross-sectional SUA phenotypes and longitudinal patterns. Risk factors for longitudinal patterns were assessed through logistic regression.

      Results

      a significant/borderline improvement of asthma control outcomes in the last 2–4 weeks emerged at follow-up with respect to baseline for: daily activities limitations (Δ −16%), frequent diurnal symptoms (Δ −25%), uncontrolled asthma symptoms according to ACT (Δ −26%). Last 12-month use of oral corticosteroids was less frequent at follow-up than at baseline (Δ −25%). Health status improvement was confirmed by lung function test results.
      Through LTA, two longitudinal patterns were detected considering last 12-month control outcomes: “persistence/worsening” (53.9%), “under control/improvement” (46.1%). A lower likelihood of having “persistence/worsening” SUA was exhibited by patients under anti-IgE (OR 0.38, 95% CI 0.17–0.84) and inhaled corticosteroids-bronchodilator association treatment (OR 0.13, 95% CI 0.01–1.26, borderline value), while a higher likelihood was shown by older age at first asthma diagnosis (OR 1.04, 95% CI 1.01–1.07).

      Conclusion

      the implementation of a SUA registry, the availability of patient-level data and the application of an innovative longitudinal analysis allowed to observe a general improvement in asthma control, one year after baseline, and a lower risk of SUA “persistence/worsening” in patients under anti-IgE and regular ICS-bronchodilator association use.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Respiratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • ISAR Study Group
        International severe asthma registry: mission statement.
        Chest. 2020; 157: 805-814
        • Israel E.
        • Reddel H.K.
        Severe and difficult-to-treat asthma in adults.
        N. Engl. J. Med. 2017; 377: 965-976
      1. Gibson G.J. Loddenkemper R. Sibille Y. Lundbäck B. The European Lung White Book. Respiratory Health and Disease in Europe. European Respiratory Society, Sheffield2013
        • Canonica G.W.
        • Colombo G.L.
        • Bruno G.M.
        • Di Matteo S.
        • Martinotti C.
        • Blasi F.
        • Bucca C.
        • Crimi N.
        • Paggiaro P.
        • Pelaia G.
        • Passalacqua G.
        • Senna G.
        • Heffler E.
        • SANI Network
        Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry.
        World Allergy Organ J. 2019; 12100007
        • Engelkes M.
        • de Ridder M.A.
        • Svensson E.
        • Berencsi K.
        • Prieto-Alhambra D.
        • Lapi F.
        • Giaquinto C.
        • Picelli G.
        • Boudiaf N.
        • Albers F.C.
        • Cockle S.M.
        • Bradford E.S.
        • Suruki R.Y.
        • Brusselle G.G.
        • Rijnbeek P.R.
        • Sturkenboom M.C.
        • Verhamme K.M.
        Multinational cohort study of mortality in patients with asthma and severe asthma.
        Respir. Med. 2020; 165105919
        • Wenzel S.
        Severe asthma: from characteristics to phenotypes to endotypes.
        Clin. Exp. Allergy. 2012; 42: 650-658
        • Maio S.
        • Baldacci S.
        • Cecchi L.
        • Viegi G.
        The severe asthma registries: a way tobetter know and fight the disease.
        Eur Ann Allergy Clin Immunol. 2021; 53: 99-102
        • Maio S.
        • Baldacci S.
        • Bresciani M.
        • Simoni M.
        • Latorre M.
        • Murgia N.
        • Spinozzi F.
        • Braschi M.
        • Antonicelli L.
        • Brunetto B.
        • Iacovacci P.
        • Roazzi P.
        • Pini C.
        • Pata M.
        • La Grasta L.
        • Paggiaro P.
        • Viegi G.
        • AGAVE group. RItA
        The Italian severe/uncontrolled asthma registry.
        Allergy. 2018; 73: 683-695
        • Burn J.
        • Sims A.J.
        • Patrick H.
        • Heaney L.G.
        • Niven R.M.
        Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohortstudy using evidence from the UK Severe Asthma Registry.
        BMJ Open. 2019; 9
        • Graff S.
        • Brusselle G.
        • Hanon S.
        • Sohy C.
        • Dupont L.
        • Peche R.
        • Michils A.
        • Pilette C.
        • Joos G.
        • Lahousse L.
        • Lapperre T.
        • Louis R.
        • Schleich F.
        Anti-Interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry.
        J. Allergy Clin. Immunol. Pract. 2022; 10 (01015-1): 467-477
        • Senna G.
        • Guerriero M.
        • Paggiaro P.L.
        • Blasi F.
        • Caminati M.
        • Heffler E.
        • Latorre M.
        • Canonica G.W.
        • SANI
        SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma.
        Clin. Mol. Allergy. 2017; 15: 9
        • Micheletto C.
        • Bilò M.B.
        • Antonicelli L.
        • Bresciani M.
        • D'Amato G.
        • De Benedictis E.
        • De Michele F.
        • Gasparini S.
        • Giovannini M.
        • Musarra A.
        • Vaghi A.
        • IRSA
        Severe asthma in adolescents and adults: a national, multicenter registry in real life.
        Eur Ann Allergy Clin Immunol. 2018; 50: 196-201
        • Solidoro P.
        • Nicola S.
        • Ridolfi I.
        • Canonica G.W.
        • Blasi F.
        • Paggiaro P.
        • Heffler E.
        • Bagnasco D.
        • Patrucco F.
        • Ribolla F.
        • Bucca C.
        • Rolla G.
        • Albera C.
        • Brussino L.
        Biologics in severe eosinophilic asthma: three-year follow-up in a SANI single center.
        Biomedicines. 2022; 10: 200
        • Maio S.
        • Baldacci S.
        • Simoni M.
        • Angino A.
        • La Grutta S.
        • Muggeo V.
        • Fasola S.
        • Viegi G.
        • On behalf of the AGAVE Pisa group
        Longitudinal asthma patterns in Italian adult general population samples: host and environmental risk factors.
        J. Clin. Med. 2020; 9: 3632
        • Bousquet J.
        • Mantzouranis E.
        • Cruz A.A.
        • Aït-Khaled N.
        • Baena-Cagnani C.E.
        • Bleecker E.R.
        • Brightling C.E.
        • Burney P.
        • Bush A.
        • Busse W.W.
        • Casale T.B.
        • Chan-Yeung M.
        • Chen R.
        • Chowdhury B.
        • Chung K.F.
        • Dahl R.
        • Drazen J.M.
        • Fabbri L.M.
        • Holgate S.T.
        • Kauffmann F.
        • Haahtela T.
        • Khaltaev N.
        • Kiley J.P.
        • Masjedi M.R.
        • Mohammad Y.
        • O'Byrne P.
        • Partridge M.R.
        • Rabe K.F.
        • Togias A.
        • van Weel C.
        • Wenzel S.
        • Zhong N.
        • Zuberbier T.
        Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.
        J. Allergy Clin. Immunol. 2010; 126: 926-938
        • Miller M.R.
        • Hankinson J.
        • Brusasco V.
        • Burgos F.
        • Casaburi R.
        • Coates A.
        • Crapo R.
        • Enright P.
        • van der Grinten C.P.
        • Gustafsson P.
        • Jensen R.
        • Johnson D.C.
        • MacIntyre N.
        • McKay R.
        • Navajas D.
        • Pedersen O.F.
        • Pellegrino R.
        • Viegi G.
        • Wanger J.
        • ATS/ERS Task Force
        Standardisation of spirometry.
        Eur. Respir. J. 2005; 26: 319-338
        • Boudier A.
        • Curjuric I.
        • Basagaña X.
        • Hazgui H.
        • Anto J.M.
        • Bousquet J.
        • Bridevaux P.O.
        • Dupuis-Lozeron E.
        • Garcia-Aymerich J.
        • Heinrich J.
        • Janson C.
        • Künzli N.
        • Leynaert B.
        • de Marco R.
        • Rochat T.
        • Schindler C.
        • Varraso R.
        • Pin I.
        • Probst-Hensch N.
        • Sunyer J.
        • Kauffmann F.
        • Siroux V.
        Ten-year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts.
        Am. J. Respir. Crit. Care Med. 2013; 188: 550-560
        • Collins L.M.
        • Lanza S.T.
        Fitzmaurice G.M. Johnstone I.M. Molenberghs G. Scott L. Smith A.F.M. Tsay R.S. Weisberg S.P. Latent Class and Latent Transition Analysis with Applications in the Social, Behavioral, andHealth Sciences; Wiley Series in Probability and Statistics 2010; Balding D, Cressie NAC. A John Wiley & Sons, Inc., Hoboken, NJ, USA2010: 1-283
        • Chung K.F.
        • Wenzel S.E.
        • Brozek J.L.
        • Bush A.
        • Castro M.
        • Sterk P.J.
        • Adcock I.M.
        • Bateman E.D.
        • Bel E.H.
        • Bleecker E.R.
        • Boulet L.-P.
        • Brightling C.
        • Chanez P.
        • Dahlen S.-E.
        • Djukanovic R.
        • Frey U.
        • Gaga M.
        • Gibson P.
        • Hamid Q.
        • Jajour N.N.
        • Mauad T.
        • Sorkness R.L.
        • Teague W.G.
        International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
        Eur. Respir. J. 2014; 43: 343-373
        • Hassan M.
        • Davies S.E.
        • Trethewey S.P.
        • Mansur A.H.
        Prevalence and predictors of adherence to controller therapy in adult patients with severe/difficult-to-treat asthma: a systematic review and meta-analysis.
        J. Asthma. 2020; 57: 1379-1388
        • Maurer C.
        • Raherison-Semjen C.
        • Lemaire B.
        • Didi T.
        • Nocent-Ejnaini C.
        • Parrat E.
        • Prudhomme A.
        • Oster J.-P.
        • Coëtmeur D.
        • Debieuvre D.
        • Portel L.
        Severe adult asthma and treatment adherence: results of the FASE-CPHG study.
        Rev. Mal. Respir. 2021; 38: 962-971
        • Terzano C.
        • Cremonesi G.
        • Girbino G.
        • Ingrassia E.
        • Marsico S.
        • Nicolini G.
        • Allegra L.
        • PRISMA (PRospectIve Study on asthMA control) Study Group
        1-year prospective real life monitoring of asthma control and quality of life in Italy.
        Respir. Res. 2012; 13: 112
        • Thomas M.
        Why aren't we doing better in asthma: time for personalised medicine?.
        NPJ Prim Care Respir Med. 2015; 2515004
        • Chipps B.E.
        • Haselkorn T.
        • Paknis B.
        • Ortiz B.
        • Bleecker E.R.
        • Kianifard F.
        • Foreman A.J.
        • Szefler S.J.
        • Zeiger R.S.
        Epidemiology and natural history of asthma: outcomes and treatment regimens study group. More than a decade follow-up in patients with severe or difficult-to-treat asthma: the Epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) II observational study.
        J. Allergy Clin. Immunol. 2018; 141: 1590-1597
        • Gibson P.G.
        Monitoring the patient with asthma: an evidence-based approach.
        J. Allergy Clin. Immunol. 2000; 106: 17-26
        • Reddel H.K.
        • Bacharier L.B.
        • Bateman E.D.
        • Brightling C.E.
        • Brusselle G.G.
        • Buhl R.
        • Cruz A.A.
        • Duijts L.
        • Drazen J.M.
        • FitzGerald J.M.
        • Fleming L.J.
        • Inoue H.
        • Ko F.W.
        • Krishnan J.A.
        • Levy M.L.
        • Lin J.
        • Mortimer K.
        • Pitrez P.M.
        • Sheikh A.
        • Yorgancioglu A.A.
        • Boulet L.P.
        Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.
        Eur. Respir. J. 2021; 592102730
        • Haselkorn T.
        • Fish J.E.
        • Zeiger R.S.
        • Szefler S.J.
        • Miller D.P.
        • Chipps B.E.
        • Simons F.E.R.
        • Weiss S.T.
        • Wenzel S.E.
        • Borish L.
        • Bleecker E.R.
        • TENOR Study Group
        Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in the Epidemiology and Natural History of Asthma: outcomes and Treatment Regimens (TENOR) study.
        J. Allergy Clin. Immunol. 2009; 124: 895-902
        • Haselkorn T.
        • Szefler S.J.
        • Chipps B.E.
        • Bleecker E.R.
        • Harkins M.S.
        • Paknis P.
        • Kianifard F.
        • Ortiz B.
        • Zeiger R.S.
        Disease burden and long-term risk of persistent very poorly controlled asthma: TENOR II.
        J. Allergy Clin. Immunol. Pract. 2020; 8: 2243-2253
        • Izadi N.
        • Baraghoshi D.
        • Curran-Everett D.
        • Zeiger R.S.
        • Szefler S.J.
        • Covar R.A.
        Childhood asthma management program research group. Factors associated with persistence of severe asthma from late adolescence to early adulthood.
        Am. J. Respir. Crit. Care Med. 2021; 204: 776-787
        • de Nijs S.B.
        • Venekamp L.N.
        • Bel E.H.
        Adult-onset asthma: is it really different?.
        Eur. Respir. Rev. 2013; 22: 44-52
        • Trivedi M.
        • Denton E.
        Asthma in children and adults-what are the differences and what can they tell us about asthma?.
        Front Pediatr. 2019; 7: 256
        • Almqvist L.
        • Rönmark E.
        • Stridsman C.
        • Backman H.
        • Lindberg A.
        • Lundbäck B.
        • Hedman L.
        Remission of adult-onset asthma is rare: a 15-year follow-up study.
        ERJ Open Res. 2020; 6 (00620-2020)
        • Almeida P.C.A.
        • Ponte E.V.
        • Souza-Machado A.
        • Cruz A.A.
        Longitudinal trends in clinical characteristics and lung function of patients with severe asthma under treatment in Brazil.
        BMC Pulm. Med. 2016; 16: 141
        • Zazzali J.L.
        • Raimundo K.P.
        • Trzaskoma B.
        • Rosén K.E.
        • Schatz M.
        Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
        Allergy Asthma Proc. 2015; 36: 283-292
        • Abraham I.
        • Alhossan A.
        • Lee C.S.
        • Kutbi H.
        • MacDonald K.
        Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
        Allergy. 2016; 71: 593-610
        • Vaník P.
        • Novosad J.
        • Kirchnerová O.
        • Krčmová I.
        • Teřl M.
        • Czech Anti-IgE Registry collaborators
        Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry.
        Allergy Asthma Clin. Immunol. 2020; 16: 81
        • Harrison T.
        • Canonica G.W.
        • Chupp G.
        • Lee J.
        • Schleich F.
        • Welte T.
        • Valero A.
        • Gemzoe K.
        • Maxwell A.
        • Joksaite S.
        • Yang S.
        • Howarth P.
        • Van Dyke M.K.
        Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
        Eur. Respir. J. 2020; 562000151
        • Eger K.
        • Kroes J.A.
        • Brinke A.T.
        • Bel E.H.
        Long-term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation.
        J. Allergy Clin. Immunol. Pract. 2021; 9: 1194-1200
        • Global Initiative for Asthma
        Global strategy for asthma management and prevention.
        (Available from:)
        • Bougas N.
        • Just J.
        • Beydon N.
        • De Blic J.
        • Gabet S.
        • Lezmi G.
        • Amat F.
        • Rancière F.
        • Momas I.
        Unsupervised trajectories of respiratory/allergic symptoms throughout childhood in the PARIS cohort.
        Pediatr. Allergy Immunol. 2019; 30: 315-324
        • Garden F.L.
        • Simpson J.M.
        • Mellis C.M.
        • Marks G.B.
        • Investigators C.A.P.S.
        Change in the manifestations of asthma and asthma-related traits in childhood: a latent transition analysis.
        Eur. Respir. J. 2016; 47: 499-509
        • Campos A.C.P.
        • Amorim L.D.A.F.
        • Strina A.
        • Barreto M.L.
        Understanding the dynamics of asthma symptoms between childhood and adolescence using latent transition analysis.
        Int. J. Publ. Health. 2020; 65: 957-967
        • Soto-Ramírez N.
        • Ziyab A.H.
        • Karmaus W.
        • Zhang H.
        • Kurukulaaratchy R.J.
        • Ewart S.
        • Arshad S.H.
        Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability.
        J. Epidemiol. 2013; 23: 399-410
        • Depner M.
        • Fuchs O.
        • Genuneit J.
        • Karvonen A.M.
        • Hyvärinen A.
        • Kaulek V.
        • Roduit C.
        • Weber J.
        • Schaub B.
        • Lauener R.
        • Kabesch M.
        • Pfefferle P.I.
        • Frey U.
        • Pekkanen J.
        • Dalphin J.C.
        • Riedler J.
        • Braun-Fahrländer C.
        • von Mutius E.
        • Ege M.J.
        • PASTURE Study Group
        Clinical and epidemiologic phenotypes of childhood asthma.
        Am. J. Respir. Crit. Care Med. 2014; 189: 129-138